Skip to Content

During the funding lapse, is not being supported. If data feeds are not available from GPO, will not be updated, so please use the official edition of the Federal Register on Govinfo ( If there is a technical issue with the Public Inspection List, you can view the documents on public inspection at our office in Washington, DC or on


Notice Pursuant to The National Cooperative Research and Production Act of 1993-Technologies for Target Assessment

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Notice is hereby given that, on August 1, 2002, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Technologies for Target Assessment has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are Paradigm Genetics, Inc., Research Triangle Park, NC; and LION Bioscience, Cleveland, OH. The nature and objectives of the venture are to assemble and develop a software suite and data solution that allows users to better identify targets of lead compound discovery and product development by integrating large streams of biological and biochemical data from heterogeneous sources into coherent data sets that accurately represent underlying biological relationships. If successful, the project will lead to a Start Printed Page 57854Target Assessment Technologies Suite (TATS) of software and database products applicable to any organism or cell culture system. TATS goes beyond data integration to allow researchers to create, validate and analyze coherent data sets to identify high quality targets. The ability to compare data across multiple research platforms in a way that is biologically relevant and statistically sound will greatly improve the ability to identify gene function and increase the number of product leads that succeed in clinical trials in the pharmaceutical and agrochemical industries.

Start Signature

Constance K. Robinson,

Director of Operations, Antitrust Division.

End Signature End Preamble

[FR Doc. 02-23112 Filed 9-11-02; 8:45 am]